Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 7, 2010, Pages 3093-3098

  Chen, Yao Tseng ^a   Chadburn, Amy ^a   Lee, Peishan ^b   Hsu, Melinda ^b   Ritter, Erika ^b   Chiu, April ^a   Gnjatic, Sacha ^b   Pfreundschuh, Michael ^c   Knowles, Daniel M ^a   Old, Lloyd J ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Cancer vaccine target; Immunotherapy; Tumor immunology

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN CT45; RECOMBINANT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; GRAY ZONE LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOID HYPERPLASIA; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; SEROLOGY;

ANTIGENS, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; LYMPHOMA, B-CELL; REED-STERNBERG CELLS;

HUMAN HERPESVIRUS 4;

EID: 77649241293     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0915050107     Document Type: Article

References (27)

1. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267-268.
2. Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014-2021.
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625.
4. van der Bruggen P, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
5. Chen YT, et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914-1918.
6. Jäger E, et al. (2000) Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760-4765.
7. Davis ID, et al. (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101:10697-10702.
8. Jäger E, et al. (1999) Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events. Int J Cancer 84:506-510.
9. Marchand M, et al. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230.
10. Chen YT, et al. (2005) Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci USA 102:7940-7945.
11. Chen YT, et al. (2009) Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Int J Cancer 124:2893-2898.
12. De Smet C, Lurquin C, Lethé B, Martelange V, Boon T (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327-7335.
13. De Smet C, Loriot A, Boon T (2004) Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 24:4781-4790.
14. Güre AO, Wei IJ, Old LJ, Chen YT (2002) The SSX gene family: Characterization of 9 complete genes. Int J Cancer 101:448-453.
15. Xie X, et al. (2003) Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas. Clin Cancer Res 9:167-173.
16. Lim SH, Austin S, Owen-Jones E, Robinson L (1999) Expression of testicular genes in haematological malignancies. Br J Cancer 81:1162-1164.
17. Colleoni GW, et al. (2002) Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma. Hum Pathol 33:496-502.
18. Chambost H, et al. (2000) Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 95:3530-3533.
19. Heidebrecht HJ, et al. (2006) Characterization and expression of CT45 in Hodgkin's lymphoma. Clin Cancer Res 12:4804-4811.
20. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC (2000) Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 86:749-751.
21. Rudolph P, et al. (1999) Ki-A10, a germ cell nuclear antigen retained in a subset of germ cell-derived tumors. Am J Pathol 154:795-803.
22. Jungbluth AA, et al. (2005) The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106:167-174.
23. Poppema S, Potters M, Emmens R, Visser L, van den Berg A (1999) Immune reactions in classical Hodgkin's lymphoma. Semin Hematol 36:253-259.
24. Schreck S, et al. (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27:31-39.
25. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339.
26. Hans CP, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282.
27. Gnjatic S, Old LJ, Chen YT (2009) Autoantibodies against cancer antigens. Methods Mol Biol 520:11-19.